3 result(s) for 'CD4'
1 - 3 of 3 results for 'CD4'
Sort by
Show
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...
Introduction to immuno oncology
1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies
2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers
3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...
Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA
I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2
Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learning...